Compugen (NASDAQ:CGEN) Stock Price Crosses Above 200-Day Moving Average - What's Next?

Key Points

• Compugen crossed above its 200-day moving average; the 200-day MA is $1.92, the stock traded as high as $2.73 and last at $2.64 on volume of about 473,175 shares.
• The company reported a substantial quarterly beat with EPS $0.60 vs. $0.05 expected and revenue $67.33M versus $14.30M, showing strong margins and return on equity.
• Analysts hold a “Moderate Buy” consensus with an average target of $5.00 after mixed ratings (several buy/strong-buy initiations and one sell), and institutional ownership is roughly 12% with recent stake increases by firms like Jane Street.

Compugen Ltd. (NASDAQ:CGEN - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.92 and traded as high as $2.73. Compugen shares last traded at $2.64, with a volume of 473,175 shares traded.

Analyst Upgrades and Downgrades

CGEN has been the topic of several analyst reports. HC Wainwright initiated coverage on shares of Compugen in a research report on Wednesday, January 7th. They issued a "buy" rating and a $4.00 target price on the stock. Truist Financial raised shares of Compugen to a "strong-buy" rating in a research report on Wednesday, March 25th. Wall Street Zen raised shares of Compugen from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Compugen in a research report on Monday, April 20th. Finally, Lake Street Capital initiated coverage on shares of Compugen in a research report on Tuesday, April 7th. They issued a "buy" rating and a $6.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Compugen Stock Down 2.6%

The stock's 50-day moving average is $2.32 and its 200 day moving average is $1.92. The stock has a market capitalization of $249.61 million, a PE ratio of 7.14 and a beta of 2.79.

Compugen (NASDAQ:CGEN - Get Free Report) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $0.55. Compugen had a net margin of 48.57% and a return on equity of 55.68%. The firm had revenue of $67.33 million for the quarter, compared to the consensus estimate of $14.30 million. As a group, equities research analysts forecast that Compugen Ltd. will post -0.26 EPS for the current year.

Institutional Trading of Compugen

Several large investors have recently added to or reduced their stakes in CGEN. Franklin Resources Inc. bought a new stake in Compugen in the second quarter worth approximately $56,000. Jane Street Group LLC grew its position in Compugen by 1,077.0% in the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company's stock worth $700,000 after acquiring an additional 359,785 shares in the last quarter. Osaic Holdings Inc. grew its position in Compugen by 346.0% in the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company's stock worth $78,000 after acquiring an additional 34,045 shares in the last quarter. Two Sigma Investments LP grew its position in Compugen by 10.6% in the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company's stock worth $291,000 after acquiring an additional 18,929 shares in the last quarter. Finally, Raymond James Financial Inc. grew its position in Compugen by 51.0% in the third quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company's stock worth $149,000 after acquiring an additional 34,215 shares in the last quarter. 12.22% of the stock is owned by institutional investors.

Compugen Company Profile

Compugen Ltd. NASDAQ: CGEN is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.